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1. Introduction 
The objective of this paper is to introduce a new chapter in protein analyses and profiling in 
general, and to discuss on the potential practical implementation in detecting neurological 
diseases. A need for such a research occurs due to the arguable fact that new techniques and 
methods for protein analyses have been developing, and only a few have actually been 
implemented in routine clinical practice. This study is a part of a larger effort to develop 
methods in order to understand protein diversity and specificity of a human proteome in health 
and disease. Primarily, we will introduce and discuss some standard and already implemented 
techniques in clinical practice, and further we will focus on the new methods for cerebrospinal 
fluid (CSF) analysis as a primary biological media for study of neurological diseases. 
1.1 Proteins in neurological diseases 
Neurological conditions in patients occur as a result of a structural or biochemical 
abnormality in the brain, spinal cord or in the nerves leading to and from them. After the 
onset of symptoms, additional parameters are analyzed in order to distinguish between 
different, so called, patterns and contribute to the diagnosis of a disease. Protein profiling 
has been introduced in clinical practice 100 years ago (W. Bruno 1956; Vesterberg 1989). 
Cerebrospinal fluid is the media used for such investigations, due to its close proximity to 
the brain; therefore being a biological fluid that can potentially obtain first-hand information 
about the potential causes of the induced change. Changes usually occur either in the CSF 
physical appearance, or can be manifested through the intrinsic characteristics – mainly the 
protein content and composition. Protein profiling in neurological diseases, therefore, 
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contributes to the overall clinical diagnosis. However, in order to acquire the complete 
clinical state in a patient one must include comparative protein analysis in the other 
biological fluids (serum, plasma or urine). Since proteins in CSF are derived from the 
plasma, changes in the composition or concentration in either of these media will result in 
changes in the other (Andersson, Alvarez-Cermeno et al. 1994). Total protein concentration 
reveals only little about the function of blood-brain barrier and exploits changes only after 
the onset of symptoms related to a neurological disorder. Also, there are neurological 
disorders, among others multiple sclerosis, which are characterized with normal or 
moderately increased total protein concentration (although changes in the individual 
protein concentration occurs) (Link and Muller 1971). This serious neurological disorder, 
and many others, mostly related to demyelization processes in the CNS; do not exhibit 
changes in total protein concentration (Hein Nee Maier, Kohler et al. 2008). Other 
neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), or 
amyotrophic lateral sclerosis (ALS) have different causes and affect different regions of the 
nervous system, and are characterized by abnormal accumulation of protein aggregates and 
organelles along the axon due to disruption of axonal transport. As a consequence, an early 
pathogenic event leading to the demise of neurons occurs (Chevalier-Larsen and Holzbaur 
2006; De Vos, Grierson et al. 2008). This remark only contributes to the importance of 
analyzing proteins and protein profiles in such diseases.  
In order to achieve our goal and to be able to correlate proteins to certain disease, we must 
first address to understanding the origin of the complexity of the proteome in human cells 
and body fluids. The importance of studying cells at the proteome level is underscored by 
the difficulty in predicting protein characteristics from genomic sequence data alone. These 
characteristics include post-translational modifications, subcellular distribution, stability, 
biomolecular interactions, and function. In contrast to DNA and RNA, proteins can be 
modified by phosphorylation, glycosylation, acetylation, nitrosation, poly(ADP 
ribosylation), ubiquitination, farnesylation, sulfation, linkage to glycosyl-
phosphatidylinositol anchors, and SUMOylation. In total, there are about 300 different 
posttranslational modifications that have been reported. These modifications can 
profoundly affect protein conformation, stability, localization, binding interactions, and 
function (Aebersold and Goodlett 2001). Separate media further complicate the application 
of protein analyses. Cerebrospinal fluid is a hurdle media for protein analyses for one basic 
reason - limited amount of starting material that is often insufficient to carry out all the 
analysis required. Additional reasons for the difficult analysis of body fluid proteome is 
their large dynamic range reflected by the presence of very abundant proteins like albumin, 
and in the case of CSF, minute quantities of brain-derived proteins (Anderson and Anderson 
1998). Further complicating the analysis of CSF is the possible infiltration of serum proteins 
that is caused by a leaky blood-brain barrier that is especially pronounced in patients with 
brain disorders. As a consequence, it is often impossible to know if a protein that is found in 
CSF is derived from the brain or serum. And not only proteins fitting in a specific family, 
but the separate protein fractions, and moreover, the individual proteins and even protein 
variants, produce useful information about the presence of all types of disorders. 
Considerable fact is that additional modifications in proteins occur after translation of the 
information written in the genes. Having this remark in mind, it is obvious that the 
proteome is practically more related to the phenotype of an individual, and hence, protein 
profiling will result in the most precise understanding of disease mechanisms as well as the 
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molecular effects of drugs (Turck, Maccarrone et al. 2005).  The ultimate goal of proteomics 
in medicine, and its sub disciplines is therefore, to provide quantitative and qualitative data 
of sample proteins that reflect a certain phenotype, disease state or a response to disease 
treatment. 
1.2 Methods for protein analysis 
Analyzing proteins as a diagnostic parameter in clinical practice was introduced with the 
development of the traditional techniques that combined methods based on protein 
precipitation and colored reactions. Since the introduction of electrophoresis in routine 
protein profiling in patients with neurological diseases, the main goal is developing novel 
methods for protein analyses that will offer more information and onset into the intrinsic 
protein characteristics. In recent years, almost every approach used to describe a method or 
technique applied to study protein diversity is termed “proteomics”(Nedelkov 2005). 
Analyses in proteomics, especially when human plasma proteome is considered, are 
technically challenging because the circulating proteome is a complex mixture of diverse 
proteins that spans approximately 10 orders of magnitude in concentration (Anderson and 
Anderson 2002). Routine techniques in protein profiling include mainly electrophoretic 
methods and can be distinguished as: gel-based proteomics approaches, fractionation or 
separation with other media and support material, which are based toward the 
identification of abundant proteins. For these types of assays, experimental designs need to 
involve enrichment strategies such as immunoisolation of protein complexes of interest to 
reduce sample complexity and increase sensitivity of detection. 
The development of non-gel-based approaches for quantitative proteomics, together with 
advances made to detect posttranslational modification guide progress toward delineating 
the mechanisms involved in nerve regeneration and degeneration dysfunctions. Such 
neuroproteomics approaches lay the foundation for further detailed functional studies (Sun 
and Cavalli 2010). Both of these approaches relay on a two stage mechanism of protein 
analysis: protein separation followed by identification and analysis (Turck, Maccarrone et al. 
2005). Classical proteomic approaches employ fractionation on the protein level with the 
help of 2D-PAGE. This technique produces high resolution protein separations resulting in 
the display of potentially thousands of protein spots. Identification of these spots is rather 
difficult and requires additional informatics-based approaches in order to derive relevant 
conclusions. Some of the limitations of 2D-PAGE have currently been overcome with the 
implementation of 2D-DIGE (Difference Gel Electrophoresis) where fluorescent dyes are 
used to distinguish between proteins from control samples and one from individuals with 
certain disease (Alban, David et al. 2003). It is therefore evident that at this point in 
proteomic technology development the broadest proteome coverage comes from a 
combination of multidimensional fractionation, advanced instrumentation and additional 
computational techniques. 
Introducing mass spectrometry in protein analysis contributes towards overcoming several of 
the disadvantages common for standard techniques. The most efficient and most widely used 
protein identification method in proteomics are MALDI-TOF-MS, SELDI-TOF-MS, ESI-
MS/MS and other methods (Lahm and Langen 2000; Issaq, Veenstra et al. 2002). Using shot-
gun mass spectrometry approach proteins are digested by specific enzymes into small 
peptides and analyzed on-line by MS. This technique allows low abundant proteins to be 
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identified despite the presence of high abundant proteins in the samples. Further advantage 
was done by Aebersold and co-workers (Gygi, Rist et al. 1999). They have developed a novel 
isotope-coded affinity tag (ICAT) strategy that permits the stable-isotope labeling of cysteine 
residues in proteins, thus facilitating a quantitative global analysis of differences in protein 
expression. A more common approach is combining chromatography separation (usually 
liquid chromatography, since proteins are high molecular mass compounds) with mass 
spectrometry detection. Chromatographic methods reduce the complexity of protein mixtures 
on the basis of different binding principles, and every approach adds a unique resolving 
power. The proteins are usually separated on the basis of affinity, charge, hydrophobicity, or 
size (Fountoulakis, Takacs et al. 1999; Takacs, Rakhely et al. 2001). The choice of the 
chromatographic method best-suited to fulfill the experimental requirements is essential for 
the success of the experiment (Fountoulakis and Takacs 1998). There are several 
methodologies that use liquid chromatography (mainly HPLC) as a tool for protein separation. 
Basic LC-MS/MS techniques generally employ ion-pair reversed-phase chromatography 
followed by electrospray ionization and mass spectrometry analysis. Depending on the 
ionization technique, LC –MS/MS coupling can be done either “on-line” (where HPLC is 
directly coupled to the ESI source of the tandem MS) or “off-line” (where, after being resolved 
in the HPLC process, samples are deposited directly onto a MALDI target, mixed with 
corresponding matrix and analyzed via MALDI-TOF MS) (Mallick and Kuster 2010). In the last 
15 years combined approaches coupling immunoaffinity separation and mass spectrometry 
detection have been implemented (Nedelkov 2006). Also, a new approach that is considered 
promising in the efforts of proteome analysis is the use of aptamers as an alternative class of 
reagents to use for highly multiplexed protein measurements (Brody, Gold et al. 2010). 
All of the above mentioned protein composition studies can be extended to two main 
approaches – analyzing either individual proteins or obtaining protein profile (“group” 
protein analysis). 
1.2.1 Protein profiling approach 
In the “group” protein analysis, termed as protein profiling, our main focus is to detect and 
identify as many proteins as possible, perform qualitative analyses, and obtain protein 
pattern for each sample analyzed (Fig.1/a). 
Electrophoresis techniques have been the hub of laboratory testing and a component of 
almost all diagnostic panels (McCudden, Voorhees et al. 2010). A rather intriguing fact is 
however, that electrophoresis has come only a short way in advancing during the years, 
when used for protein profiling in patients with neurological diseases. Since it was 
implemented as a method in routine clinical practice, electrophoresis has come only a short 
way in actually progressing. In routine clinical practice discontinuous polyacrylamide gel 
electrophoresis (DISC-PAGE) is usually applied for determining the protein profile 
(Monteoliva and Albar 2004). More detailed information can be obtained using denaturing 
sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) (Hu, Huang et al. 
2004). In diagnosing some specific neurological diseases, isoelectric focusing (IEF) and 
immunofixation can be used to confirm the presence of specific oligoclonal, monoclonal or 
polyclonal immunoglobulin. Determination of these protein components is in many cases 
necessary to delineate between differential diagnoses. By combining IEF with gel 
electrophoresis, two dimensional gel electrophoresis is created (2D-GE), a technique, which 
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is probably the most frequently used methodology for protein profiling. When applied into 
clinical practice, this methodology is used to analyze the complete proteome present in 
tissue samples, biological fluids and cell lysates. The result is an electrophoregram (for 1D-
GE techniques) or pattern plot (for 2D-GE) fingerprinting the specific protein composition in 
the analyzed sample. 
 
 
 
(a) (b) 
 
 
Fig. 1. Methods for protein analyses a) protein profiling using microchip electrophoresis,  
b) single protein analysis using mass spectrometry immunoassay (MSIA) 
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The general goal when using these types of qualitative group approaches is obtaining 
complete protein profiles both, from control samples and samples from patients with 
different (neurological) diseases. By comparing the obtained protein profile from the control 
subject (normal reference sample) to a profile originating from a patient we are able to 
construct a certain pattern based on the principal of similarity analysis (Trenchevska, 
Aleksovski et al. 2009). In our work, using this approach, we have been able to implement 
microchip electrophoresis method to distinguish a specific pattern for several neurological 
diseases (multiple sclerosis, blood-brain barrier dysfunction diseases, inflammatory 
conditions and autoimmune disorders) which will be discussed further in details. 
1.2.2 Single protein assays 
Although, the classical proteomics efforts are geared towards the analysis of the protein 
constitutes in both CSF and serum (Maccarrone, Birg et al. 2004; Maccarrone, Milfay et al. 
2004), alternative strategies have been established for the identification of novel disease 
markers for neurological disorders. When it comes to protein analyses, often the 
concentration plays a significant role in contributing to diagnosis (example – determination 
of IgG concentration in multiple sclerosis). However, quantitation of all proteins in a sample 
is a Herculean task itself, due to the fact that the outcome of a proteome profiling 
experiment results in a content-rich and convoluted data that require powerful approaches 
to discover the subtle differences between the healthy and diseased samples (Figure 1a). In 
this regard, mass spectrometry has found its way as a sensitive technique for quantitative 
protein analyses. Although mass spectrometry has been a golden standard for proteomics 
from the very beginning, its complexity, cost, maintenance and other analytical 
characteristics are the underlying reason why this technique is rarely used in routine clinical 
practice (Rabilloud 2002). A step forward has been done with introducing immunoaffinity 
approaches (Engvall and Perlmann 1971; Ritchie 1999; Craig, Ledue et al. 2001; Yan, Lee et 
al. 2004). The pilot work has been done with introducing ELISA as a technique for 
quantification single proteins from biological samples. This technique is currently the most 
common abandoned method used in routine screening of known proteins and is commonly 
used as a laboratory test for detecting antibodies or rapidly screen and quantify antigens in 
biological samples. Several advantages have made this technique favorable; it follows 
simple sample preparation, it does not require specific conditions and data acquisition is 
relatively simple (Dufva and Christensen 2005). However, it can only be applied in 
analyzing known proteins, and, what is more, a suitable antibody must exist for retrieving 
the antigens from the sample. Also, ELISA based methods determine the total protein 
concentration and are lacking the ability to detect, identify or quantify protein variants, 
post-translational modifications or point mutations. Therefore, advances in this area are 
directed in developing assays that use combined techniques in order to obtain more detailed 
information about each protein intrinsic characteristics. Combined techniques have been 
conceptualized in the mid-nineties, via the SELDI (Hutchens and Yip, US patent 
No.5,719,060) (Engwegen, Gast et al. 2006; Poon 2007), and later by MSIA (Nelson et al., US 
patent No.6,974,704)(Nelson, Krone et al. 1995; Krone, Nelson et al. 1996) approach. The 
newly developed methodologies are the platform for biomarker discovery assays. These 
assays target “individual” proteins and use specific antibody towards the protein of interest. 
These specific proteins from the proteome are considered to be potential diagnostic markers 
for certain neurological diseases. MSIA methodology, which will be further discussed in 
details, bridges between the selectivity that can be obtained with immunoassays and the 
specificity of mass spectrometry detection (Fig. 1/b).   
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2. Electrophoresis in protein profiling 
Identification and determination of different types of proteins play an important role in 
medical diagnosis. Conventional electrophoresis methods are well known for protein detection 
and analysis in several biological fluids, primarily blood serum and plasma and cerebrospinal 
fluid. CSF analysis, coupled with other methods, remains the cornerstone of diagnosis of 
various neurological diseases, including multiple sclerosis (Reiber, Otto et al. 2001; Sindic, Van 
Antwerpen et al. 2001). Even though electrophoresis is practically the basic technique in 
protein profiling, both in routine and scientific clinical practice, it provides only semi-
quantitative information about the concentration of a certain protein. Regarding the protein 
profiling, these techniques still offer significant amount of information, especially about the 
abundance of specific protein classes, such as immunoglobulins. This is of great importance in 
demyelization neurological diseases. Additional criteria for this and other types of 
neurological diseases are presence of oligoclonal immunoglobulins. For detection of 
oligoclonal IgG in serum and unconcentrated CSF, several techniques can be used, primarily 
isoelectric focusing (IEF) combined with polyethylene-enhanced gel immunofixation and 
silver staining, CSF:serum quotient diagram and body index (Tourtellote, Povin et al. 1980; 
Sandic, Monteyne et al. 1994; Mitrevski, Stojanoski et al. 2001). Combining IEF and PAGE, 2D-
GE methods are developed, optimizing techniques for detailed protein mapping, as mentioned 
previously. Introducing bioinformatics tools is further implemented in order to obtain more 
information from the protein profile. This approach necessitates usage of protein standards in 
each run. Using additional computational programs and following the advances in the field of 
bioinformatics, more information can be obtained from each protein profile spectra.  
2.1 Conventional DISC-PAGE and IEF 
Discontinuous polyacrylamide gel electrophoresis (DISC-PAGE) is one of the most widely 
used techniques for analytical separation of proteins and peptides. DISC-PAGE separations 
are based upon the intrinsic protein charge-to-mass ratio and the molecular mass of the 
protein (Chiou 1999). Polyacrylamide gels are thermostable, transparent, strong and 
chemically inert, can be prepared in different pore concentration and are non-ionic, 
therefore making them convenient for protein analyses (Ornstein 1964). Presented in Fig.2 
are electrophoregrams obtained from normal samples (Fig.2/a) and sample from patient 
with blood-brain barrier disfunction (Fig.2/b) using DISC-PAGE classical method, 
implemented in routine clinical practice. Each protein zone can be identified and quantified 
according to the peak area and when compared to standard. The obtained results for the 
basic parameters in protein profiling using DISC-PAGE are presented in Table 1.  
 
Protein fraction 
Optical 
density 
Peak 
area 
Band % Rf 
Prealbumin 44.97 1.984 2.31 0.071
Albumin 240.97 5.332 46.92 0.201
┙ – globulins 45.73 1.984 3.58 0.368
┚1 –globulins 52.44 1.736 4.03 0.461
┚2 –globulins 186.52 3.534 20.27 0.594
┛ -globulins 106.48 2.046 7.85 0.683
 
Protein fraction
Optical  
density 
Peak 
area 
Band % Rf 
Prealbumin 52.91 4.026 4.72 0.095 
Albumin 207.6 6.138 37.97 0.299 
┙ – globulins 70.89 2.640 5.93 0.442 
┚1 –globulins 187.8 4.686 22.01 0.620 
┚2 –globulins 133.2 1.650 7.45 0.694 
┛ -globulins 158.8 4.092 21.93 0.817 
a) b) 
Table 1. Characteristic parameters for protein profile obtained using DISC-PAGE from a) 
control group (normal sample) and b) sample from patient with neurological disorder. 
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a) b) 
Fig. 2. Electrophoregrams presenting protein profile from CSF samples obtained from a) 
control group (normal sample) and b) sample from patients with disfunction in blood-brain 
barrier 
2.2 Miniaturization in electrophoresis 
The miniaturization processes have been implemented in all spheres of protein research, 
resulting in newly developed techniques that follow the concept of microchip 
electrophoresis. The onset of miniaturization electrophoresis dates from 1954 when the 
first microchip used in the semiconductors structure was created (Manz, Graber et al. 
1990). It took more than 20 years to introduce the first microchip in gas chromatography 
analyses in 1975. However, the great leap in applying miniaturization in biomedical 
sciences and research was in the beginning of 1990s, when the first commercial microchip 
was constructed (Woolley and Mathies 1994; Keramas, Perozziello et al. 2004; Balslev, 
Jorgensen et al. 2006; Geschke 2006; Geschke 2009). This pioneer technique was 
introduced for the first time in genomic and DNA analysis in the mid-1990s, when the 
first commercially available microchip for DNA and RNA analyses was produced. Protein 
microchips were used for the first time in 1999, when 6 fluorescent labeled proteins with 
molecular mass ranging between 9 and 116 kDa were successfully separated on a 
microchip in less than 35 s (Yao, Anex et al. 1999). Another step forward was done in 2001 
when a method for fluorescent labeled protein-SDS complexes (where proteins were non-
covalently bounded to the denaturing agent) separation was optimized (Jin, Giordano et 
al. 2001). The first commercially available microchip was known as LabChip and 
produced by Bousse et al. (Bousse, Mouradian et al. 2001) in Caliper Technologies, 
Mountain View, CA. At the same time, Agilent 2100 Bioanalyzer appears on the market, 
as the first commercial instrument for microchip electrophoresis separation platforms.  
The preliminary results using microchip technology indicated great potential, especially 
for implementation in routine clinical practice, which was the basic goal of developing 
such methods.  
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2.3 Use of lab-on-a-chip electrophoresis in protein profiling 
Miniaturized lab-on-a-chip electrophoresis is a novel technique in protein profile analyses, 
introduced with the development of Agilent 2100 Bioanalyzer (Woolley and Mathies 1994). 
The microchip system includes system of microchannels through where gel is rushed by 
applying pressure. The gel contains fluorescent dye which serves as a label; therefore 
protein detection is done by fluorescence analysis. By running the chip, proteins can be 
separated according to their size, and, as a result, protein profile can be obtained. Looking 
into the basics of lab-on-a-chip electrophoresis it can be noted that the basis of analysis is 
denaturing SDS-PAGE; therefore proteins separate only according to their molecular mass 
and not their charge. The microchip platform consists of a system of micro-channels ranging 
in width from 20 to 100 µm and height of 10-25 µm. Protein separation is performed in a 
solid media (polyacrylamide gel) both in native and denaturing conditions. Gel preparation 
is performed in a buffered solution, therefore presenting the necessary ions for the protein 
separation. Created potential difference indicated protein movement through the system of 
channels. During their passing through the system, proteins form an affinity bond to a 
fluorescent dye, therefore becoming visible for detection. Using a highly sensitive 
fluorescent detector, signals from the proteins are noted and protein profile can be obtained 
from a single sample in less than one minute (Trenchevska, Aleksovski et al. 2009). LiF 
detector is commonly used due to its high selectivity and sensitivity – it can detect 
fluorescein concentration in 300 fM quantities (Ocvirk, Tang et al. 1998). This detection 
method is actually the critical point that allows protein analysis in such a short time.    
Lab-on-a-chip protein electrophoresis employs several advantages when compared to other 
types of electrophoresis. It is significantly faster, shortening the time required per analysis, 
which is of great importance, especially for application in clinical laboratories where a large 
cohort of samples is analyzed on daily basis. Further, the amount of sample required for the 
analysis is only 5 µL, which is convenient especially when proteins in CSF are analyzed. 
Also, unlike traditional electrophoresis techniques, lab-on-a-chip method uses fluorescent 
detector, which has higher sensitivity. The microchip is designed in a specific manner 
depending on the analysis required, whether it is DNA, RNA or protein. Regarding the 
proteins in neurological diseases, using this technique under optimized conditions, we were 
able to analyze both low molecular mass proteins (MW<50 000 Da) and high molecular mass 
proteins (50 000 Da < MW < 250 000 Da) (Auroux, Iossifidis et al. 2002). 
2.3.1 Method development 
In order to obtain better resolution and assay characterization, several modifications can be 
made. Lab-on-a-chip electrophoresis platform does not usually allow many modifications; 
however, several optimizations can contribute to obtaining better results. This technique so 
far is very well implemented in DNA and RNA assays, but its application in protein 
analyses is rather limited for several reasons. Lab-on-a-chip electrophoresis system uses 
fluorescent detector, therefore require fluorescent dyes for protein labeling. These types of 
dyes, however, do not form covalent bond with the labeled protein; therefore require longer 
incubation times in order to allow high-efficient specific binding (Floriano, Acosta et al. 
2007). Having this in mind, Giordano et al. introduced a concept that significantly reduces 
these effects. It was noted that using SDS as denaturing agent incorporated in the gel, 
besides uniformly charging the proteins, favorizes their binding with the fluorescent dye, 
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further producing higher signal to the detector (Christodoulides, Floriano et al. 2007; 
Floriano, Acosta et al. 2007; Sloat, Roper et al. 2008). When biological samples are analyzed, 
further problems in developing the assay occur, due to the intrinsic complexity of the 
specimen itself. In order to obtain the protein profile using lab-on-a-chip electrophoresis, 
several conditions must be optimized.  
Sample preparation for lab-on-a-chip electrophoresis - prior to analysis samples were 
stored at -20ºC for two weeks. Serum and cerebrospinal fluid samples from control group 
(designated as normal according to their cross-reactivity toward the usual infectious agents 
and donor information), and from patients with different neurological diseases (primarily 
multiple sclerosis, than blood-brain barrier disfunction and other demyelization diseases) 
were used for the analyses. Samples were prepared by combing 84 µL sterile water, 4 µL 
sample and 2 µL denaturing agent (BME). Within each run, protein standard (ladder) was 
used for calibration and protein fraction identification.   
Optimization of denaturing agent concentration – denaturation agents contribute to easier 
formation of protein-fluorescent dye complex therefore resulting in higher efficiency of the 
detector. In the sample optimization steps, we have incubated the samples with different 
concentration of denaturing agent beta-mercaptoethanol (BME). Sample to denaturing agent 
ratio used for the analysis were – 1:1; 1:1.5; 1:2; 1:2.5; 1:3; 1:3.5 and 1:5. The results have been 
previously published and have shown optimal protein to BME ratio of 1:3.5 (Trenchevska, 
Aleksovski et al. 2009). 
Optimization of incubation temperature – Temperature is an important parameter in 
protein analyses due to its effect onto the protein structure (denaturation) and affinity 
towards the fluorescent dye, which, in turn can cause increase of the signal in the detector. 
When optimizing incubation temperature, samples were incubated in water bath at five 
different temperatures – 5ºC, 22ºC (room temperature), 37ºC (normal body temperature), 
60ºC and 90ºC. It was noted that optimal incubation temperature is 90ºC (Trenchevska, 
Aleksovski et al. 2009). 
Assay procedure – After sample preparation and following incubation under the optimized 
conditions, the microchip was placed in the bioanalyzer and run. In the process of 
electrophoretic separation in the bioanalyzer, the electric current provides ideal conditions 
for staining and destaining within 45 s per sample analyzed. During the separation process, 
the sample is initially rushed through the pores in polyacrylamide gel, and then allowed to 
bind with the fluorescent dye incorporated into the microchannels. When using denaturing 
conditions, further SDS binding causes proteins to gain net negative charge, therefore 
separating proteins in a sample only according to the molecular mass.   
Results processing – After completion of the separation process, complete numerical 
analysis is necessary in order to obtain more information from the protein profile for each 
sample. Analyses regarding statistical parameters are important in clinical practice, because, 
in a time scale, they provide useful information about the distribution of specific protein 
fractions and their relation to a specific disease. Collecting such large amount of data is 
enabled due to the automation and development of microcomputers. Using Web-based 
databases, data acquisition, manipulation and computation for electrophoresis protein 
pattern recognition is further performed using standard statistical signal analysis (Spirovski, 
Stojanoski et al. 2005). In this context, the next promising area of interest is cluster analysis, 
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along with artificial neural networks, bioinformatics techniques that have been successfully 
applied to various areas in medical practice, as diagnostic systems (Vogt and Nagel 1992; 
Jerez-Aragones 2003), biomedical analysis (Lisboa 2002) and neuroimaging (Aizenberg, 
Aizenberg et al. 2001).  
In our work, using the optimized lab-on-a-chip electrophoresis method, we were able to 
obtain the protein profile from patients with multiple sclerosis, neurodegenerative diseases 
and blood-brain dysfunction and further perform statistical analysis on the obtained data.  
2.3.2 Application in clinical practice (profiling in patients with different neurological 
disorders) 
Lab-on-a-chip electrophoresis was used in order to confirm the “group” aspect approach in 
protein profiling that is of great significance in every day clinical practice. Protein profiles 
from patients were classified in one of the four major types according to the distribution of 
the five basic protein zones: prealbumin, albumin, ┙-globulin, ┚-globulin and ┛-globulin – 
normal (N), transudative (T), gamaglobuline (┛) and transudative-gamaglobuline (T┛). 
When compared to protein standard, in each of the zones, different proteins can be 
identified. This identification, however, offers only qualitative details, and cannot be used in 
quantifying separate proteins with high accuracy. We have previously reported using the 
optimized lab-on-a-chip electrophoresis to analyze serum and cerebrospinal fluid samples 
from control group and patients with neurological diseases (Trenchevska, Aleksovski et al. 
2009). It was noted that using this advanced technique, protein profiles can be used to obtain 
satisfactory qualitative analyses, therefore contributing to precise clinical diagnosis. In 
patients with multiple sclerosis, for example, characteristic electrophoretic patterns were 
noted, characterized by high IgG concentration (which is evident in 46% of all MS cases, 
where intrathecal IgG synthesis occurs), and normal total protein levels (Fishman 1992; 
Daskalovska 2000). Examples of the electrophoregrams for both normal samples and 
samples from patient with multiple sclerosis are presented in Figure 3.  
3. Mass spectrometry-based protein identification protocols 
Mass spectrometry has been used in clinical practice mainly for detection of small 
molecules (MW<1 kDa) aiming to detect inborn errors in metabolism, or monitoring 
toxicity, drug and doping abuse (Ahmed 2008). Introduction to mass spectrometry in 
proteomics was made possible in recent years thanks to the discovery of the so called soft 
ionization techniques (ESI and MALDI) that were recognized by the Nobel Prize in 
chemistry 2002 (Tanaka, Waki et al. 1988; Fenn, Mann et al. 1989). Using either ESI or 
MALDI, a molecular mass with a precision and accuracy of ±0.05% or better can be 
achieved. This depends heavily on the purity of the protein sample, the relative size of the 
protein, the presence or absence of post-translational modifications, the resolution of the 
mass spectrometer itself and so on. Mass spectrometry has been broadly used in 
determination of protein amino acid sequence using either tandem mass spectrometry 
MS/MS sequencing of enzymatically derived peptide fragments of the original protein, or 
sometimes direct MS/MS on the intact protein. Using these approaches, post translational 
modifications such as protein phosphorylation, sulfonation, oxidation and terminal amino 
acid cleavage can be identifyed. Over the past few years, the sensitivity and specificity of 
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mass spectrometry coupled with liquid chromatography, have improved to a degree such 
that protein quantification can be derived from very complex mixtures (tissues, biofluids, 
cell lysates etc.). Recent publications contribute to the newly developed methods for 
protein characterization, identification and quantification, especially regarding low 
abundant proteins in biological specimen (Gygi, Rist et al. 1999; Kiernan, Nedelkov et al. 
2006) 
 
Fig. 3. Characteristic electrophoregrams obtained using lab-on-a-chip protein 
electrophoresis in samples from a) control group (normal sample); b) sample from patient 
with multiple sclerosis; c) sample from patient with polyradiculoneuropathy; d) sample 
from patient after ictus cerebralis; e) sample from patient with blood-brain barrier 
disfunction and f) control sample. Noted in the electrophoregrams are differences in the 
protein distribution primarily in the ┛-globulin region, which is expected in samples from 
patients with demyelization processes, where intrathecal IgG synthesis is dominant. 
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To use mass spectrometry for biomarker discovery in clinical proteomics is conceptually 
simple. What we do is compare obtained spectral peaks from specific protein or proteins in 
body fluids or tissue extracts in a diseased group, with those from the control group. These 
peaks correspond to potential biomarker molecules. MS biomarker discovery efforts have 
focused on four subsets of the proteome: (i) polypeptides and whole proteins in tissues  or 
body fluids separated by electrophoresis or chromatography, with or without 
prefragmentation; (ii) enzymatic peptide fragments separated by HPLC and analyzed by ESI 
or MALDI; (iii) proteins in tissue or body fluids that are adsorbed on surface protein ships in a 
matrix, analyzed by SELDI and (iv) naturally occurring fragmented peptides in blood that 
represent low range of the plasma/serum proteome, analyzed by MALDI (van der Merwe, 
Oikonomopoulou et al. 2007). In our work, we mainly concentrate in analyzing intact proteins 
as potential biomarkers using one of the basic approaches – top down proteomic analysis.     
3.1 Top-down proteomics analysis 
As a tool for proteins and peptides separated by electrophoresis or chromatography, and 
with or without previous fragmentation, mass spectrometry has been applied in several 
different ways; the two approaches are top-down and bottom-up MS. Top-down MS is the 
direct analysis of proteins on the intact level. Bottom-up approach identifies proteins 
following enzymatic or chemical digestion of the sample resulting in the formation of much 
smaller peptide fragments. These smaller protein segments are much easier to analyze with 
low resolution MS instruments and therefore bottom-up peptide analysis is currently the 
most popular MS-based proteomics approach (Han, Jin et al. 2006). 
The strength of top-down proteomics approach lies in the direct detection of the native 
molecular mass of biological protein species. Mass spectrometry detection provides 
information for the native protein, and also for the natively occurring small peptides, 
biologically generated protein cleavages, post-translational modifications or point mutations 
– all of which are postulated to be relevant in many diseases and other biological processes 
occurring in cells. Other major advantage of top-down approach is the simplified sample 
preparation that does not necessitate enzymatic or chemical digestion prior to analysis. 
Scientist using top-down approach in studying proteins are mainly oriented towards 
addressing clinical questions – using population screening in the complicated process of 
identification and validation of potential biomarkers (Whitelegge, Halgand et al. 2006). 
Several techniques are favored in top-down proteomics research platform. SELDI-TOF MS is 
a widely used biomarker discovery method that combines the selectivity of chromatography 
and sensitivity of mass spectrometry detection. The major challenge for this approach is the 
requirement for off-line enrichment and purification of the selected biomarker candidates, 
followed by MS/MS identification using different MS platform(Reid and McLuckey 2002).  
MALDI-TOF MS has also found its way in implementing in top-down proteomics quest for 
novel biomarkers. One of the disadvantages of the methods used in routine clinical 
biomarker discovery techniques is the complicated sample preparation which requires 
chromatographic or electrophoretic separation of the targeted protein. Immunoaffinity 
capture of a protein directly from a biological sample is a base method used in all 
immunoassays (such as ELISA). Therefore, by combining the selectivity of immunoaffinity 
capture and the specificity of mass spectrometry, a novel methodology has been developed 
in recent years– Mass Spectrometry Immunoassay (MSIA).  
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In our work we have developed several assays using MSIA approach. Using this novel 
platform we were able to analyze several proteins, some of which have been introduced as 
potential biomarkers for several neurological diseases. An introduction to the overall 
procedure and application of this technique will be introduced through the development of 
Cystatin C MSIA assay. 
3.2 Mass spectrometry immunoassay (MSIA) 
Mass Spectrometry Immunoassay (MSIA) is a novel approach that has been employed for 
both, qualitative and quantitative characterization of body fluid proteins. From the 
methodology point of view, it is a combination of today’s predominant technology involved 
in routine clinical practice – immunoassay for targeted protein affinity extraction assessment 
and uses mass spectrometry detection (MALDI-TOF-MS) for achieving the specificity 
necessary for this type of analyses. This approach lacks the disadvantage demonstrated by 
the immunoassays – inability to detect protein variants, post translational modifications or 
mutations. On the contrary, MSIA gives onset into the detailed intrinsic protein 
characteristics, both for high or low abandoned proteins. One great advantage of this hybrid 
methodology is the simplicity of protein extraction from complicated biological samples. 
The basic concept of the analysis includes a two-step approach; first, proteins are captured 
by a principle of microscale affinity by aspiration/dispense cycles on an antibody-
derivatized affinity pipette, and in the second step eluted proteins are subsequently 
analyzed using MALDI-TOF-MS (Fig.4) 
 
Fig. 4. Mass spectrometry immunoassay scheme 
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In the initial stage of this method’s development, agarose beads derivatized with an affinity 
ligand (e.g. polyclonal antibodies) were used to create a µL-scale column inside a 
micropipette tip (Krone, Nelson et al. 1996). These columns are further derivatized with a 
corresponding antibody toward the targeted protein. Additional activation of the beads is 
necessary prior to the derivatization process. A summary of the consecutive steps in 
activation and derivatization of the affinity pipettes is presented in Figure 5.  
 
Fig. 5. Affinity pipettes activation and derivatization procedure 
When the affinity pipettes are coated with the corresponding antibody, further activation of 
the surface is needed in order to favor protein binding. Using Multimek 96 automated 96-
channel pipettor (Beckman Coulter, Brea, CA, USA), the antibody coated affinity pipettes 
were rinsed with buffer (PBS, with 0,1%TWEEN) in 10 aspiration/dispense cycles. Next, 
pipettes were immersed into a microplate containing the sample (serum, plasma, urine or 
CSF). Following additional buffer rinse (in order to elute the non-specific bounded proteins 
or other constitutes origin from the sample) and two water rinse cycles, retrieved targeted 
protein on the affinity pipette is ready for discharge. Figure 6 illustrates the steps in this 
analysis. 
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Fig. 6. Steps in MSIA protein analysis 
Preparing for the second step of detection – the mass spectrometry detection, captured 
protein is eluted directly on the MALDI target, by 6 µL aliquots of MALDI matrix (┙-cyano-
4-hydroxycinnamic acid in aqueous solution containing 33% (v/v) acetonitrile and 0.4% 
(v/v) trifluoroacetic acid). Using this acidic matrix, captured protein are dissociated from 
the antibodies and eventually dispensed onto the target. Following drying and visual 
inspection of the sample spots, linear mass spectra were acquired using delayed extraction 
mode with 1.7 kV draw out pulse, 200 ns delay and a full accelerating potential of 20 kV.  
 
 MSIA 
 Qualtitative MSIA Quantitative MSIA 
Primary goal Population proteomic studies
Biomarker discovery and 
validation 
Samples Large cohort of samples 
Control and disease samples 
spiked with reference protein 
Assay development 
Affinity pipettes immobilized 
with antibody toward 
targeted protein 
Affinity pipettes immobilized 
with two antibodies – toward 
targeted protein and IRS 
Immunoaffinity 
separation 
Retrieval of targeted protein 
Retrieval of targeted protein 
and the IRS 
Mass spectrometry 
detection 
MALDI-TOF MS MALDI-TOF MS 
Results 
Detection of protein variants, 
post-translational modification 
and point mutation 
Calculating concentration of 
native protein and protein 
variants 
Additional analyses Enzymatic digestion / 
Table 2. Differences between qualitative and quantitative MSIA approaches 
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Although introduced in the recent years, this technique has already been implemented in 
developing qualitative and quantitative assays for several protein and protein variants using 
different biological samples as medium. There is one basic difference regarding these two 
approaches (Table 2). When using MSIA platform for qualitative analysis, affinity pipettes 
are derivatized only with antibody towards the targeted protein; additional antibody must 
be fitted into the affinity micocolumn in order to retrieve another protein in the quantitative 
assay. In quantitative MSIA, affinity pipettes are derivatized with a secondary antibody, 
toward a protein termed as internal reference standard (IRS). Choosing the IRS is one of the 
critical steps in developing of the assay, due to the high criteria required for such a protein. 
An important prerequisite for an IRS is that it should not be present in human plasma or 
serum (or other biological fluids, as well), so that its spiked concentration in the analytical 
samples is always constant. Also, the signal on the mass spectrometer produced by the IRS 
should be in close proximity to the signal of the targeted protein, in order to be able to use 
the same MS acquisition parameters for both proteins. The goal in developing qualitative 
assays is determination and identification of existing or novel protein variants and point 
mutations. In these type of analyses, a large cohort of samples is required for analyses in 
order to delineate between the “wild” isoforms (post-translational modifications, or 
additional derivatization) present in majority of samples, and which subsequently are 
termed as “normal” and the pathological variants which are only present in a small number 
of samples or in samples from patients with certain diseases. In quantitative assays we are 
able to calculate the exact concentration of each variant, which, again, by screening 
populations, can provide information about the range of “normal” concentration 
distribution of the variant and the protein in general. These correlations can further be used 
in discussing the potential biomarker capacity of a certain protein or variant. Presented here 
are results of the developed MSIA qualitative and quantitative assays for determination of 
cystatin C and its variants. 
3.2.1 Qualitative CysC MSIA assay in CSF and serum 
Cystatin C is a serine proteinase inhibitor belonging to the type 2 cystatin gene family 
(Jarvinen, Rinne et al. 1987; Mussap and Plebani 2004). It inhibits both endogenous 
proteases, such as liposomal cathepsins, and proteases of parasites and microorganisms. It is 
a non-glycosilated single chain protein with a molecular weight of 13,343. Due to the 
important function, cystatin C is expressed at the stable levels in most nuclear cells. Its 
amino acid sequence consists of 120 amino acid residues encoded by a 7.3 kb gene located in 
chromosome 20 (Schnittger, Rao et al. 1993). Cystatin C has been indicated in numerous 
pathological states (Henskens, Veerman et al. 1996; Grubb 2000; Reed 2000), most notably in 
renal failure (Randers, Kristensen et al. 1998; Randers and Erlandsen 1999). There are a 
growing number of reports demonstrating that cystatin C is more preferable than creatinine 
for measurement of GFR (Naruse, Ishii et al. 2009).  Also, a variant of human cystatin C 
(L68Q) is an amyloidogenic protein deposited in the cerebral vasculature of patients with 
hereditary cerebral hemorrhage with amyloidosis in which patients suffer from repeated 
cerebral hemorrhages (Ghiso, Jensson et al. 1986; Olafsson and Grubb 2000; Calero, Pawlik 
et al. 2001).  In the clinical practice, cysC is well-desribed serum marker of renal failure that 
is not dependent of age, sex or lean muscle mass (Seronie-Vivien, Delanaye et al. 2008; 
Naruse, Ishii et al. 2009). At the same time, cystatin C is becoming acknowledged as a 
marker for elevated risk of death from myocardial infraction and stroke(Naruse, Ishii et al. 
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2009). The concentration of cystatin C in healthy individuals range from 0.8 to 1.2 mg/L, 
depending on the measurement method (Roos, Doust et al. 2007). Increased serum levels are 
almost always associated with reduction in GFR. The role of cystatin C as potential 
biomarker for multiple scleroses was introduced in the work of Irani et al. They have 
reported a correlation between the ratio of one cysC truncated form des-SSPGKPPR and 
native cysC peak, and the occurrence of multiple sclerosis(Irani, Anderson et al. 2006). Other 
research groups do not support this concept, claiming that the cleaved peptide occurs as a 
result of sample storage, not exclusively MS existence (Del Boccio, Pieragostino et al. 2006; 
Hansson, Hviid Simonsen et al. 2006; Nakashima, Fujinoki et al. 2006). 
 
Fig. 7. Cystatin C mass spectra showing signal from native form and additional “wild type” 
protein variants 
In previous work MSIA assays have been developed for qualitative identification of cystatin 
C from human plasma (Kiernan, Nedelkov et al. 2006) and urine samples (Kiernan, Tubbs et 
al. 2003). After several assay optimization we were able to develop MSIA assay for 
determination of cysC in cerebrospinal fluid both from control group and a couple of 
matched serum/CSF samples obtained from patients with multiple sclerosis(Trenchevska, 
Aleksovski et al. 2009). 
MSIA provides excellent results for this type of single protein analysis, because it preserves 
the protein in its native form during the sample preparation procedure, and using the 
MALDI-TOF MS, allows an insight into the detailed protein structure, presence and 
distribution of isoforms. When completing MSIA data from analyzed cysC in human plasma 
sample, besides the native peak (CysC native MW=13 343), several protein variants can be 
noted: oxidation peak (MW=13 359), des-S variant (MW=13 260) and des-SSP variant (MW= 
13 076) (Fig.7) 
These isoforms were noted in all samples analyzed, and also in a large population 
proteomics study where 1000 samples were screened using the developed MSIA cystatin C 
assay (Nedelkov, Tubbs et al. 2004; Nelson, Nedelkov et al. 2004). The goal of the further 
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research was to develop MSIA method for cysC identification in CSF. For utilization of this 
assay, a critical step was sample preparation in terms of optimizing the dilution. In this 
analysis, both control CSF samples and samples from patients diagnosed with MS were 
analyzed. Moreover, paired serum/CSF samples origin from same individuals was 
screened. As presented in the previous studies, using the optimized MSIA qualitative assay, 
cysC and its wild type isoforms were detected in the analyzed CSF samples (Nedelkov, 
Shaik et al. 2008). However, several correlations were observed when matched serum/CSF 
samples were analyzed. The sample that consisted most extensive truncations in the serum 
cysC, exploits most variants in the CSF sample as well (Fig.8/c,d). Also, additional peaks 
not common in serum cysC analysis were noted both in the control CSF samples and the 
samples from patients with MS. These are mainly truncated cysC isoforms missing 3, 4, 7, 8, 
9, 10, 11, 14 and 17 N-terminal amino acids; some of which have been reported for the first 
time by our group (Fig. 8/a,b). 
 
 
 
 
 
 
Fig. 8. MALDI-TOF MS spectra obtained after cystatin C MSIA in a) serum sample (control); 
b) CSF sample (control); c) paired serum/CSF sample (control) and d) paired serum/CSF 
sample (patients with diagnosed multiple sclerosis) (reprinted with permission from 
(Nedelkov, Shaik et al. 2008)) 
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3.2.2 Developing quantitative MSIA assay for CysC and its variants 
Developing quantitative assays for protein determination can contribute to the diagnosis 
and prognosis in clinical proteomics studies due to the fact that oftentimes, not only the 
occurrence, but also the concentration distinguishes between “normal” and “diseased” 
condition. Using conventional ELISA and other immunologically based quantitative assays, 
we can obtain information about the total protein concentration. All these techniques, 
however, lack the ability to quantify specific protein variants and isoforms, which in turn, 
are more probable biomarker candidates.  
Using MSIA, we have been able to develop and validate several fully quantitative assays, 
both for quantitation of intact proteins, as well as protein isoforms.  
There are several possible approaches regarding mass spectrometry quantitation of proteins 
and protein variants. One requires usage of isotope labels, whereas, second uses different 
protein, termed as internal reference standard for quantitation. The goal of developing 
platforms to be implemented in every-day clinical practice requires simplified sample 
preparation procedure and handling. In our work we present the developed quantitative 
assay for determination and quantitation of cystatin C and its variants in biological samples. 
Results from this quantitative assay have recently been published (Trenchevska and 
Nedelkov 2011). In this chapter we summarize the basic concepts and “hot spots” that need 
to be considered when developing this type of assay in clinical practice. The procedure 
includes several steps: 
Choice of internal reference standard – There are several approaches in the process of 
choosing an adequate internal reference standard for a quantitative assay. An important 
prerequisite that an internal standard must possess is not to be present in human plasma or 
serum, so that its spiked concentration in the analytical sample remains constant in each 
analysis. Also, the signals that the IRS produces in the mass spectra should be in close 
proximity to the signal of the targeted protein, so that the same MS acquisition parameters 
can be used for analysis of both proteins. For developing quantitative assay for cysC we 
have used beta-lactoglobulin (BL), the major whey protein in cow’s milk, which has 
molecular weight of 18 281 (it is close to the MW of cysC = 13 343), and is present in many 
mammalian species, but not in human. In Figure 9, signals from cystatin C and the internal 
reference standard BL can be noted.   
Optimization of standard curve concentration range – In this step first it is necessary to 
determine the ratios of immobilized cysC and BL antibodies immobilized on the affinity 
pipettes. In general, concentration of cysC antibody should be higher in order to 
accurately quantify the various amounts of cysC in the examined analytical samples. Since 
we can control the concentration of BL in the samples, the antibody concentration can be 
lower in the affinity pipettes. For the analysis we have used the following antibody ratio – 
cysC:BL=8.5:1 (m/m). Next, we determine the optimal concentration and volume of 
spiked BL in the samples, and last, we determine the concentration range for the standard 
curve. It is important to construct the curve in its linear range concentration and then 
dilute the samples if necessary, because of the greater accuracy. In this assay we have 
constructed a six point cysC standard curve, spanning the range from 0.0312 to 1.0 mg/L 
cystatin C (Fig.10). 
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Fig. 9. Mass spectra from cystatin C and Beta lactoglobulin used as internal reference 
standard for quantitation 
 
Fig. 10. Presented is a typical standard curve used for cysC quantitation (left); representative 
cysC mass spectra used for standard curve generation (right) (reprinted with permission 
from (Trenchevska and Nedelkov 2011). 
Sample preparation – Prior to the analysis, the analytical samples were diluted twice in the 
assay buffer and spiked with 5 µL BL (c (BL) =10 mg/L). 
Assay parameters – For this quantitative assay several characteristic parameters were 
analyzed in order to check the reproducibility and quality of assessment. Intra-assay 
precision was done by analyzing three plasma samples in replicates, each with a single 
standard curve. Inter-assay precision was determined by analyzing one plasma sample three 
times on different days with separate standard curve. Linearity of the assay was determined 
by analyzing serial dilutions of a sample with known cysC concentration and comparing the 
observed with the expected concentrations. Also, spiking-recovery experiments were 
performed by adding cysC standard in known concentration into the analytical sample, 
again with a known cysC concentration. By comparing the expected with the observed 
results we were able to recover the spiked cysC concentration.  
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Assay validation – In order to further validate the newly developed assay, a comparison with 
a well-established method was performed. Several samples were analyzed both with 
commercially available ELISA and with the developed MSIA method. The good correlation 
between both assays validated the results obtained with the new cystatin C assay (ref. statija 
cysC).   
Assay application – The next phase, and practically the last step between the method and its 
application in the full potential is actually screening many samples and quantifying not only 
the native protein, but the isoforms present. Using this assay, we were able to quantify 
cystatin C and its variants in a total of 500 plasma samples. For all the samples, 
concentrations of cystatin C and its variants was determined, and averaged (average cysC 
concentration = 0.94 mg/L) which corresponds to the average CysC concentration 
previously established using ELISA (Erlandsen, Randers et al. 1998). In all the samples the 
“wild type” variants were noted; CysC 3Pro-OH and two truncated forms lacking one (des-
S) and three (des-SSP) N-terminal amino acids respectably (Fig.11). 
 
Fig. 11. Typical MALDI-TOF spectra from cystatin C showing the detected variants 
Presented in Table 3 are partial results from the quantitative analysis of cystatin C, where 
we were able to calculate the concentration of each variant present in the analytical sample. 
 
sample 
Native cysC 
[mg/L] 
Hydroxyl cysC 
[mg/L] 
cysC des-S 
[mg/L] 
cysC des-SSP 
[mg/L] 
Total cysC 
[mg/L] 
1 0.25 0.33 0.07 0.07 0.71 
2 0.32 0.41 0.08 0.03 0.84 
3 0.39 0.48 0.09 0.08 1.04 
4 0.42 0.54 0.08 0.08 1.11 
5 0.35 0.46 0.11 0.11 1.02 
6 0.27 0.35 0.07 0.09 0.79 
7 0.24 0.34 0.06 0.04 0.68 
8 0.69 0.83 0.15 0.18 1.85 
9 0.45 0.58 0.12 0.11 1.27 
10 0.29 0.38 0.08 0.09 0.85 
Table 3. Example of quantitative data obtained for cystatin C protein variants 
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4. Further strategies in clinical proteomics 
From a diagnostic point of view, it is of great advantage to analyze and assess biological 
markers of disease from several biological fluids from the same individual. Albeit on a small 
scale, the results shown here indicate that such studies are possible if the right assays are 
utilized. The developed MSIA method provides a unique way of delineating protein 
isoforms and their abundance in serum and CSF. This way, additional population 
proteomics studies can be done, that will provide with further insight into the physiology of 
biological processes and diseases. Group protein profiling still remains an irreplaceable 
method in clinical practice, due to the amount of information that can be provided in a 
single analysis. When combined with the advanced methods for statistical classification and 
analysis and using the tools of bioinformatics, analyses at a large scale can be performed. 
Obtained data can further be used in creating software programs and data bases for 
recognition and identification of specific protein profiles. 
Further analyses regarding our group will progress in several directions: (1) develop 
quantitative assays for other proteins that are considered to be potential diagnostic markers 
for specific neurological diseases; (2) implement these assays to fully quantify proteins and 
protein isoforms in serum and cerebrospinal fluid samples; (3) introduce the concept of 
immunoaffinity separation techniques into clinical practice (4) develop algorithms for 
protein profile data base creation and pattern recognition and (5) investigate the possibility 
to implement the novel methods to analyze proteins using other media such as tears and 
saliva.  
5. Conclusions 
Analyzing proteins is a complicated task since many approaches can be followed 
(Andersson, Alvarez-Cermeno et al. 1994; Anderson and Anderson 1998; Bakhtiar and 
Nelson 2001; Diamandis 2003; Conrads, Hood et al. 2004; Bons, Wodzig et al. 2005; 
Anderson 2010). There are two majorly differentiated approaches that can be applied in 
routine clinical practice, analyzing protein profile (protein profiling) and choosing single 
protein (biomarker discovery) and optimizing methods for identification and 
determination. Regarding these remarks, there is a quite divergence between the 
“group” protein screening and “individual” protein determination. However, by 
combining different novel techniques we are able to bridge the gap in between. In 
addition, we can discuss the necessary development both in the methodology and 
techniques in order to have the highest impact on the study of the molecular composition 
of CSF proteins. 
The application of these novel techniques to the study of neurological disorders is providing 
an insight into the pathogenesis of neurodegeneration, and is fueling major efforts in 
biomarker discovery.In the protein profiling concept we are able to analyze patterns 
obtained from the proteome of a patient with a certain disease, and compare it with a 
sample from a control group. This approach is still widely used in screening patients with 
neurological diseases, using electrophoresis techniques as a basic technique. By comparing 
these profiles, a typical prototype pattern is created for separate conditions, and by simply 
comparing these patterns (nowadays with the use of informatics tools and statistics 
programs) differential diagnosis is possible. 
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This approach, however, only presents the big picture. It is the single protein biomarker 
assays that are more and more abundant in clinical laboratories. The quest for novel 
biomarkers results in developing techniques and mechanisms of investigating protein 
intrinsic characteristics at a molecular level.  
From the obtained results we can conclude that even though in routine clinical practice 
enzymatic immunoassays are still dominant, especially for quantitative protein analysis, 
they have one crucial disadvantage. These assays are oblivious to protein modifications, 
unless there is an antibody toward that exact modification. The mass spectrometry 
immunoassay, on the other hand, is designed to detect protein modifications and intact 
proteins in a single assay. This qualitative determination is already a way to delineate 
between control subjects and diseased samples. With the added quantitative feature, this 
and similar assays are poised to change the way we look proteins and protein modifications 
and their role in health and disease.  
An integrated evaluation of the data that are obtained by all the holistic approaches, in 
combination with clinical and epidemiological data will eventually not only increase our 
understanding of disease mechanisms, but subsequently also enable us to develop more 
specific and individualized medicines and therapies. 
All our efforts are oriented toward the main goal – to aid in the process of revealing the 
protein complexity of neurological disorders and contribute to its better understanding. 
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